Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Balsalazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.51 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.51 |
| ▸ | SIRT5 | Q9NXA8 | 5/20 | 1.00 |
| ▸ | NME4 | O00746 | 3/20 | 1.00 |
| ▸ | GCDH | Q92947 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | AVPR1A | P37288 | 1/20 | 1.00 |
| ▸ | HTR3A | P46098 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | BLVRB | P30043 | 2/20 | 0.59 |
| ▸ | PDE4A | P27815 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Balsalazide SCHEMBL3267109 | 1.00 | SIRT5 (1.00) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL29377041 | 1.00 | SIRT5 (1.00) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL118300 | 1.00 | SIRT5 (1.00) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL7908058 | 0.99 | SIRT5 (0.97) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL28818120 | 0.99 | SIRT5 (0.97) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL134019 | 0.99 | SIRT5 (0.97) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL5598491 | 0.99 | SIRT5 (0.97) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL133200 | 0.97 | SIRT5 (0.95) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL20184744 | 0.93 | SIRT5 (0.87) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL17392780 | 0.93 | SIRT5 (0.87) | SIRT5NME4GCDHTDP1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065038-A1 | New therapeutic approaches for treating Charcot-Marie-Tooth disease | Pharnext (FR) | 2009-06-03 | — | — | EP | claimed |
| US-20250257069-A1 | JAK INHIBITOR ANALOGS, FORMULATIONS, AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-08-14 | — | — | US | disclosed |
| CN-119923257-A | JAK inhibitor analogues, formulations and uses thereof | 密歇根大学董事会 | 2025-05-02 | — | — | CN | disclosed |
| EP-3735219-B1 | ORAL LIQUID PHARMACEUTICAL COMPOSITIONS OF AMINOSALICYLATES | FERRING BV (NL) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023201044-A2 | JAK INHIBITOR ANALOGS, FORMULATIONS, AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20210077415-A1 | ORAL LIQUID PHARMACEUTICAL COMPOSITIONS OF AMINOSALICYLATES | FERRING B.V. (NL) | 2021-03-18 | — | — | US | disclosed |
| CN-111954517-A | Oral liquid pharmaceutical composition of aminosalicylate | 费灵有限公司 | 2020-11-17 | — | — | CN | disclosed |
| EP-3735219-A1 | ORAL LIQUID PHARMACEUTICAL COMPOSITIONS OF AMINOSALICYLATES | Ferring B.V. (NL) | 2020-11-11 | — | — | EP | disclosed |
| CN-111529684-A | Use of oral sustained release compositions containing cyclosporin | 卓越治疗有限公司 | 2020-08-14 | — | — | CN | disclosed |
| US-20200171123-A1 | COMPOSITIONS FOR USE IN THE TREATMENT OF ULCERATIVE COLITIS | Sublimity Therapeutics Limited (IE) | 2020-06-04 | — | — | US | disclosed |
| WO-2009158384-A1 | METHODS AND KITS FOR THE TREATMENT INHIBITION, AND MAINTENANCE OF GASTROINTESTINAL DISORDERS | THE PROCTER & GAMBLE COMPANY (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20090274662-A1 | Methods And Kits For The Treatment Of Inflammatory Bowel Disorder Conditions | THE PROCTER & GAMBLE COMPANY | 2009-11-05 | — | — | US | disclosed |
| US-20090252788-A1 | Balsalazide formulations and manufacture and use thereof | SALIX PHARMACEUTICALS, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| EP-2065038-A1 | New therapeutic approaches for treating Charcot-Marie-Tooth disease | Pharnext (FR) | 2009-06-03 | — | — | EP | disclosed |
| US-20090098088-A1 | Methods And Kits For The Treatment Of Diverticular Conditions | THE PROCTER & GAMBLE COMPANY (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009048603-A1 | METHODS AND KITS FOR THE TREATMENT OF DIVERTICULAR CONDITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2009-04-16 | — | — | WO | disclosed |
| EP-1931354-A2 | BALSALAZIDE FORMULATIONS AND MANUFACTURE AND USE THEREOF | Salix Pharmaceuticals, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2008033125-A1 | METHODS OF TREATMENT FOR ULCERATIVE COLITIS USING AMINOSALICYLATE | THE PROCTER & GAMBLE COMPANY (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20070213304-A1 | Use of Aminosalicylates in Diarrhoea-Predominent Irritable Bowel Syndrome | Borody, Thomas (AU) | 2007-09-13 | — | — | US | disclosed |
| WO-2007025146-A2 | BALSALAZIDE FORMULATIONS AND MANUFACTURE AND USE THEREOF | SALIX PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200171123-A1 | COMPOSITIONS FOR USE IN THE TREATMENT OF ULCERATIVE COLITIS | SI, TPMT, FABP2 | PTGS1 254/4885PTGS2 262/4885SIRT5 2926/4885 |
| US-20250257069-A1 | JAK INHIBITOR ANALOGS, FORMULATIONS, AND USES THEREOF | JAK1, JAK3, JAK2 | PTGS1 342/4885PTGS2 484/4885SIRT5 1862/4885 |
| US-20090098088-A1 | Methods And Kits For The Treatment Of Diverticular Conditions | ALPI, SI, FABP2 | PTGS1 522/4885PTGS2 736/4885SIRT5 130/4885 |
| US-20070213304-A1 | Use of Aminosalicylates in Diarrhoea-Predominent Irritable Bowel Syndrome | SLC10A2, SI, SCN5A | PTGS1 457/4885PTGS2 624/4885SIRT5 2344/4885 |
| US-20090274662-A1 | Methods And Kits For The Treatment Of Inflammatory Bowel Disorder Conditions | SI, ALPI, FABP2 | PTGS1 616/4885PTGS2 692/4885SIRT5 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.